ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

This study has been terminated.
Sponsor:
Collaborator:
INC Research
Information provided by:
Zealand Pharma
ClinicalTrials.gov Identifier:
NCT00283361
First received: January 25, 2006
Last updated: February 27, 2007
Last verified: February 2007
  Purpose

The main purpose of this study is to see if the experimental drug ZP120, when given with the approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the amount of fluid in the patients' lungs and make breathing easier.


Condition Intervention Phase
Heart Failure, Congestive
Drug: ZP120
Procedure: I.v. catherization
Procedure: 6-minutes walk performance
Behavioral: Dyspnea severity assessment
Procedure: Blood sampling for laboratory tests
Procedure: ECG
Procedure: Physical examination
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II,Randomized, Double-Blind, Flexible Dose Study of ZP120 I.V. Infusion as Add-On Therapy in Patients With Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated With Furosemide

Resource links provided by NLM:


Further study details as provided by Zealand Pharma:

Primary Outcome Measures:
  • Change in dyspnea severity

Secondary Outcome Measures:
  • Change in 6-minute walk test performance

Estimated Enrollment: 130
Study Start Date: January 2006
Estimated Study Completion Date: December 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients, age 18 years or more
  2. A diagnosis of acute or subacute decompensated chronic heart failure, either ischemic or nonischemic, requiring hospitalization, and currently treated with furosemide, torsemide, or bumetadine, and other evidence based optimal treatment for heart failure. Patients must have the clinical diagnosis of CHF made at least 3 month prior to enrollment
  3. Ambulatory
  4. Objective signs of LVD corresponding to a LVEF < 45%, documented by any accepted method within the previous 12 months. If documentation is not available within the required time frame, LVEF must be assessed prior to enrollment
  5. a) Worsening heart failure symptoms (current NYHA class III-IV). Patients must experience worsening of at least one of the symptoms described below at the time of entry into the study:

    Dyspnea Symptoms:

    • Dyspnea (labored or difficult breathing) at rest
    • Worsening dyspnea (labored or difficult breathing) on minimal exertion
    • Worsening orthopnea (difficult breathing except in the upright position)
    • Increased frequency of nocturnal dyspnea (awaken from sleep due to respiratory distress)

      b) Clinical evidence of volume overload such as weight gain over previous few days, peripheral edema, hepatic congestion with ascites, pulmonary congestion, or pleural effusion

  6. Females of childbearing potential must have a negative pregnancy test at enrollment. A female is considered to be of childbearing potential unless she is post-menopausal (no menses for at least 12 consecutive months) or without a uterus and/or both ovaries
  7. Ability to understand and willing to sign Informed Consent Form

Exclusion Criteria:

  1. Incapable of taking the 6-minute walk test due to any condition unrelated to heart failure, e.g., muscular or skeletal disability
  2. Valvular heart disease requiring surgical intervention (during the course of the study. Patients with heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease)
  3. History of or clinically significant evidence of any severe disease other than heart failure that preclude participation and complicate the evaluation of study results from the local laboratory:

    • Hepatic disease (AST, ALT, total bilirubin > 3 times Upper Limit of Normal (ULN), renal disease (S-Creatinine > 2.5 mg/dL),
    • Uncontrolled insulin-dependent diabetes mellitus with a history of frequent hypoglycemic episodes or frequent hospitalizations for hyperglycemia,
    • Cancer (excluding treated non-melanoma skin cancer)
  4. Unstable angina, cardiogenic shock, or acute pulmonary edema requiring any of the following: Nitroprusside, intravenous nitroglycerin, nesiritide, intravenous inotrope, or need for endotracheal intubation and mechanical ventilation
  5. Acute myocardial infarction and/or myocardial infarction within 30 days (prior to enrollment) as diagnosed by investigator’s evaluation of clinical symptoms, ECG, and/or biochemical markers of cardiac injury
  6. Cardiac arrest (patients with history of cardiac arrest within 12 months unless precipitated by an event such as an acute myocardial infarction, induction by catheter placement, severe transient electrolyte abnormality, by an electrophysiology procedure, or addressed by Automatic Implantable Cardioverter Defibrillator placement. Patients with increased risk of cardiac arrest, QTc > 450 msec, atrial ventricular block II or III, etc.)
  7. Sustainable VT/VF within 30 days (> 15 seconds long; patients with enrollment ECG showing ventricular tachycardia or premature ventricular complexes associated with symptoms, or ventricular tachycardia of 6 beats)
  8. Uncontrolled atrial fibrillation on enrollment ECG with a ventricular rate >120 bpm
  9. Cardiac surgery within the last month or acutely required PCI (patients who have undergone a cardiac revascularization, valvular surgery, or biventricular resynchronization procedure within 30 days. Patients who have had ventricular reduction surgery or cardiac myoplasty and patients with mechanical ventricular assist device)
  10. Systolic blood pressure < 90 mmHg and > 200 mmHg
  11. Pulmonary embolism or DVT or history of pulmonary embolism or DVT within 6 months prior to enrollment
  12. Severe obstructive or restrictive pulmonary disease, patients with primary pulmonary hypertension and heart failure secondary to pulmonary disease, and severe pulmonary infection
  13. I.v. vasoactive treatment, e.g. vasodilators, positive inotropic agents, within 24 hours prior to enrollment (see details in Appendix E)
  14. Participation in another study evaluating an experimental treatment within the last 30 days which potentially could bias the outcome of this study
  15. Previous treatment with ZP120
  16. Patients known to abuse or actively abusing alcohol or illicit drugs. Abuse of alcohol is defined as the usual daily intake of more than 100 grams of ethanol per day, or more than approximately six 12-ounce bottles of beer, one 750 mL bottle of wine, or 250 mL of 80 proof spirits
  17. Inability or unwillingness to provide informed consent
  18. BMI outside range of 20-50 kg/m2 (BMI equal to 20 and 50 kg/m2 is accepted)
  19. Any other condition or therapy, which in the opinion of the Principal Investigator would make the patient unsuitable for this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00283361

  Show 22 Study Locations
Sponsors and Collaborators
Zealand Pharma
INC Research
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00283361     History of Changes
Other Study ID Numbers: 05-025
Study First Received: January 25, 2006
Last Updated: February 27, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on October 23, 2014